应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06978 永泰生物-B
已收盘 07-23 16:08:27
3.060
-0.190
-5.85%
最高
3.150
最低
2.910
成交量
9.40万
今开
3.150
昨收
3.250
日振幅
7.38%
总市值
15.75亿
流通市值
15.75亿
总股本
5.15亿
成交额
28.75万
换手率
0.02%
流通股本
5.15亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
ETF日报:目前医药板块处于历史较低水平,可以适当关注创新药沪深港ETF
新浪基金 · 20:09
ETF日报:目前医药板块处于历史较低水平,可以适当关注创新药沪深港ETF
永泰生物-B(06978)股价下跌8.615%,现价港币$2.97
阿斯达克财经 · 15:02
永泰生物-B(06978)股价下跌8.615%,现价港币$2.97
永泰生物-B盘中异动 股价大跌5.84%报3.061港元
自选股智能写手 · 13:15
永泰生物-B盘中异动 股价大跌5.84%报3.061港元
东海证券:关注创新药链、特色原料药等板块的投资机会
每日经济新闻 · 09:12
东海证券:关注创新药链、特色原料药等板块的投资机会
礼来(LLY)盘前涨1.4% 在华肥胖治疗领域首个创新药物替尔泊肽注射液获批
金吾财讯 · 07-22 20:54
礼来(LLY)盘前涨1.4% 在华肥胖治疗领域首个创新药物替尔泊肽注射液获批
金石亚药:公司目前暂无创新药研发或临床阶段研发项目
证券之星 · 07-22 20:01
金石亚药:公司目前暂无创新药研发或临床阶段研发项目
百诚医药:公司目前在创新药研发AIDD和CADD方面有运用AI技术
证券之星 · 07-22 19:02
百诚医药:公司目前在创新药研发AIDD和CADD方面有运用AI技术
联环药业(600513.SH)拟定增募资不超2.85亿元 用于创新药LH-1801研发项目
智通财经 · 07-22 18:08
联环药业(600513.SH)拟定增募资不超2.85亿元 用于创新药LH-1801研发项目
利好政策预计年内落地,月内近3亿资金买入港股创新药ETF(513120)
每日经济新闻 · 07-22 16:57
利好政策预计年内落地,月内近3亿资金买入港股创新药ETF(513120)
永泰生物-B盘中异动 急速下挫6.33%
自选股智能写手 · 07-22 13:24
永泰生物-B盘中异动 急速下挫6.33%
永泰生物-B(06978)股价下跌6.364%,现价港币$3.09
阿斯达克财经 · 07-22 13:23
永泰生物-B(06978)股价下跌6.364%,现价港币$3.09
【兴证医药】2024ESMO会议国产创新药品种梳理
兴证医药健康 · 07-22 11:59
【兴证医药】2024ESMO会议国产创新药品种梳理
氨基一周|BD不应该“神秘化”; 第七个被治愈的艾滋病患者出现了
氨基观察 · 07-22 11:13
氨基一周|BD不应该“神秘化”; 第七个被治愈的艾滋病患者出现了
港股异动 | 和黄医药(00013)再涨超5% 公司近期介绍创新药物进展 机构称研发进展迅速
智通财经 · 07-22 10:42
港股异动 | 和黄医药(00013)再涨超5% 公司近期介绍创新药物进展 机构称研发进展迅速
细胞免疫治疗概念盘中拉升,*ST龙津涨4.37%
自选股智能写手 · 07-22 09:50
细胞免疫治疗概念盘中拉升,*ST龙津涨4.37%
永泰生物-B盘中异动 临近收盘快速下挫7.41%报3.001港元
自选股智能写手 · 07-19
永泰生物-B盘中异动 临近收盘快速下挫7.41%报3.001港元
永泰生物-B(06978)股价下跌6.173%,现价港币$3.04
阿斯达克财经 · 07-19
永泰生物-B(06978)股价下跌6.173%,现价港币$3.04
中信建投:自免市场规模加速发展 推动国内创新药产业提质增效
智通财经 · 07-19
中信建投:自免市场规模加速发展 推动国内创新药产业提质增效
中国生物制药(01177.HK)1类创新药库莫西利胶囊的新药上市申请获受理
港股解码 · 07-18
中国生物制药(01177.HK)1类创新药库莫西利胶囊的新药上市申请获受理
中国生物制药(01177):1类创新药库莫西利胶囊“Culmerciclib(TQB3616)”新药上市申请获得受理
智通财经 · 07-18
中国生物制药(01177):1类创新药库莫西利胶囊“Culmerciclib(TQB3616)”新药上市申请获得受理
加载更多
公司概况
公司名称:
永泰生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。
发行价格:
--
{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":3.06,"timestamp":1721722107035,"preClose":3.25,"halted":0,"volume":94000,"delay":0,"floatShares":514584000,"shares":514584000,"eps":-0.69692636,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.19,"latestTime":"07-23 16:08:27","open":3.15,"high":3.15,"low":2.91,"amount":287510,"amplitude":0.073846,"askPrice":3.03,"askSize":2000,"bidPrice":2.94,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.696926368580485,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721784600000},"adr":0,"listingDate":1594310400000,"adjPreClose":3.25,"openAndCloseTimeList":[[1721698200000,1721707200000],[1721710800000,1721721600000]],"volumeRatio":2.017167,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2453362400","title":"ETF日报:目前医药板块处于历史较低水平,可以适当关注创新药沪深港ETF","url":"https://stock-news.laohu8.com/highlight/detail?id=2453362400","media":"新浪基金","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453362400?lang=zh_cn&edition=full","pubTime":"2024-07-23 20:09","pubTimestamp":1721736540,"startTime":"0","endTime":"0","summary":"7月23日大盘震荡、午后加速下跌。截至收盘,上证指数跌1.65%报2915.37点,深证成指跌2.97%,创业板指跌3.04%。量能方面,A股全天成交6668.6亿元。盘面上,银行板块逆市飘红,有色金属、电子、医药带头回调。受医药板块和芯片板块拖累,科创板表现不佳。 通信ETF今日收跌2.69%,展望后市,海内外AI需求整体强劲,光模块迭代升级需求加速,利好国内已有充分技术和客户积累的头部厂商。 目前医药板块处于历史较低水平,可以适当关注创新药沪深港ETF。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/fund/etf/2024-07-23/doc-incfcpev3393181.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2024-07-23/doc-incfcpev3393181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4550","BK1161","399300","BK1515","FDN","BK1574","BK4585","159938","06978","159982","BK4588","159992","09939"],"gpt_icon":0},{"id":"2453706700","title":"永泰生物-B(06978)股价下跌8.615%,现价港币$2.97","url":"https://stock-news.laohu8.com/highlight/detail?id=2453706700","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453706700?lang=zh_cn&edition=full","pubTime":"2024-07-23 15:02","pubTimestamp":1721718120,"startTime":"0","endTime":"0","summary":"[下跌股]永泰生物-B(06978) 股价在下午03:02比前收市价下跌8.615%,现股价为港币$2.97。至目前为止,今日最高价为$3.15,而最低价为$2.97。总成交量为7.4万股,总成交金额为港币$22.694万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152745608_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152745608_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407231840/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2453774262","title":"永泰生物-B盘中异动 股价大跌5.84%报3.061港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453774262","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453774262?lang=zh_cn&edition=full","pubTime":"2024-07-23 13:15","pubTimestamp":1721711758,"startTime":"0","endTime":"0","summary":"2024年07月23日下午盘13时15分,永泰生物-B股票出现波动,股价快速下跌5.84%。截至发稿,该股报3.061港元/股,成交量1.9万股,换手率0.00%,振幅2.77%。资金方面,该股资金流入0港元,流出5.853万港元。永泰生物-B股票所在的生物技术行业中,整体跌幅为0.26%。永泰生物-B公司简介:永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723131558941f971c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723131558941f971c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2453774001","title":"东海证券:关注创新药链、特色原料药等板块的投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2453774001","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453774001?lang=zh_cn&edition=full","pubTime":"2024-07-23 09:12","pubTimestamp":1721697141,"startTime":"0","endTime":"0","summary":"每经AI快讯,东海证券研报指出,当前医药生物行业估值处于历史低位,行业继续回调空间有限;下半年业绩有望持续向好,医疗反腐等影响因素持续弱化,中长期投资价值显著,建议关注创新药链、器械设备、医疗服务、血制品、二类疫苗、特色原料药等细分板块的投资机会。每日经济新闻...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OGHdqSIJoaklITn8DRw5TTMX5QYXqiy_YCHNrAOmN6HGsAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OGHdqSIJoaklITn8DRw5TTMX5QYXqiy_YCHNrAOmN6HGsAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240723A01NQW00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240723A01NQW00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2453767981","title":"礼来(LLY)盘前涨1.4% 在华肥胖治疗领域首个创新药物替尔泊肽注射液获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2453767981","media":"金吾财讯","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2453767981?lang=zh_cn&edition=full","pubTime":"2024-07-22 20:54","pubTimestamp":1721652874,"startTime":"0","endTime":"0","summary":"金吾财讯 | 礼来(LLY)盘前走高,暂涨1.4%,报869.49美元。近期,国家药监局官网公示,礼来申报的穆峰达(替尔泊肽注射液)长期体重管理适应证获得批准,这也是礼来肥胖治疗领域在中国获批的首个创新药物。替尔泊肽注射液本次获批的适应症为:用于在低热量饮食和增加运动基础上改善成人肥胖或伴有至少一种体重相关合并症的超重患者长期体重管理。而在今年5月,替尔泊肽已经在中国获批首个适应症,用于成人2型糖尿病患者血糖控制。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210625/OGIwZDQyMDYwMGIwOWQ1NTkxMDE1Mzc1NTA2MDQ=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OGIwZDQyMDYwMGIwOWQ1NTkxMDE1Mzc1NTA2MDQ=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278057","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0079474960.USD","LU0471298777.SGD","LU1057294990.SGD","BK4534","BK4533","IE00B4R5TH58.HKD","LU0320765059.SGD","IE00BJJMRZ35.SGD","LU0256863811.USD","LU0256863902.USD","BK1161","LU0109391861.USD","IE0004445239.USD","IE00BJT1NW94.SGD","IE00BK4W5L77.USD","LU0882574055.USD","LU1023059063.AUD","BK4581","LU0061475181.USD","GB00BDT5M118.USD","LU0672654240.SGD","LU1551013342.USD","LLY","LU0122379950.USD","LU0708995401.HKD","LU0094547139.USD","LU1551013425.SGD","LU0114720955.EUR","LU1061106388.HKD","LU1035775433.USD","IE00BJLML261.HKD","BK4007","LU0471298694.HKD","LU0417517546.SGD","159992","LU0238689110.USD","IE0002141913.USD","IE00BK4W5M84.HKD","BK4516","BK1574","LU0096364046.USD","06978","LU0943347566.SGD","LU1267930730.SGD","LU1804176565.USD","LU0289739699.SGD","LU0058720904.USD","LU1280957306.USD","BK4588","IE00B1BXHZ80.USD"],"gpt_icon":1},{"id":"2453177761","title":"金石亚药:公司目前暂无创新药研发或临床阶段研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2453177761","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453177761?lang=zh_cn&edition=full","pubTime":"2024-07-22 20:01","pubTimestamp":1721649689,"startTime":"0","endTime":"0","summary":"亚科中心产权100%由上市公司全资子公司亚克药业持有。领业医药重点布局皮肤健康领域,目前已有三十余款改良型新药和高端仿制药产品研发管线的布局。公司目前暂无创新药研发或临床阶段研发项目,感谢您的关注!公司目前经营状况平稳。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072200028885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","BK0028","BK1161","BK0077","300434","06978","159992"],"gpt_icon":0},{"id":"2453676589","title":"百诚医药:公司目前在创新药研发AIDD和CADD方面有运用AI技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2453676589","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453676589?lang=zh_cn&edition=full","pubTime":"2024-07-22 19:02","pubTimestamp":1721646124,"startTime":"0","endTime":"0","summary":"证券之星消息,百诚医药07月22日在投资者关系平台上答复投资者关心的问题。另外贵司的化合物合成业务属于生物合成范畴吗?请问公司有没有中期分红?本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072200025879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","BK0216","301096","06978","BK1161"],"gpt_icon":0},{"id":"2453567757","title":"联环药业(600513.SH)拟定增募资不超2.85亿元 用于创新药LH-1801研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2453567757","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453567757?lang=zh_cn&edition=full","pubTime":"2024-07-22 18:08","pubTimestamp":1721642920,"startTime":"0","endTime":"0","summary":"智通财经APP讯,联环药业(600513.SH)发布公告,公司拟以简易程序向特定对象发行股票,募集资金总额不超过2.85亿元(含本数),扣除发行费用后的募集资金净额将投资:创新药LH-1801研发项目、补充流动资金。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK0239","BK4196","BK4550","600513","BK4588","06978","BK4585","159992","LU0006061336.USD","LH"],"gpt_icon":0},{"id":"2453751431","title":"利好政策预计年内落地,月内近3亿资金买入港股创新药ETF(513120)","url":"https://stock-news.laohu8.com/highlight/detail?id=2453751431","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453751431?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:57","pubTimestamp":1721638627,"startTime":"0","endTime":"0","summary":"7月22日,A股、港股涨跌不一,石油、电力明显下挫,医药板块大幅反弹,相关ETF走势强劲。交易所数据显示,港股创新药ETF(513120)单日大涨2.22%,在全市场ETF中涨幅排名第3,日成交额超8.5亿元,在同类港股创新药主题ETF中排第1。截至7月19日,港股创新药ETF(513120)最新流通规模为52.5亿元,是全市场规模最大、交投最为...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OGHdqSIJoaklITn8DRw5TTMX5QYXqiy_YCHNrAOmN6HGsAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OGHdqSIJoaklITn8DRw5TTMX5QYXqiy_YCHNrAOmN6HGsAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240722A06WEQ00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240722A06WEQ00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK4585","BK1574","BK4588","BK4550","FDN","06978","BK1161"],"gpt_icon":0},{"id":"2453873375","title":"永泰生物-B盘中异动 急速下挫6.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453873375","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453873375?lang=zh_cn&edition=full","pubTime":"2024-07-22 13:24","pubTimestamp":1721625840,"startTime":"0","endTime":"0","summary":"2024年07月22日下午盘13时24分,永泰生物-B股票出现波动,股价大幅下挫6.33%。永泰生物-B股票所在的生物技术行业中,整体涨幅为1.38%。其相关个股中,华领医药-B、科伦博泰生物-B、帝王国际投资涨幅较大,振幅较大的相关个股有华领医药-B、三叶草生物-B、科伦博泰生物-B,振幅分别为15.70%、10.17%、9.01%。永泰生物-B公司简介:永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722132400aefab367&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722132400aefab367&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1574","BK1161"],"gpt_icon":0},{"id":"2453735931","title":"永泰生物-B(06978)股价下跌6.364%,现价港币$3.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2453735931","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453735931?lang=zh_cn&edition=full","pubTime":"2024-07-22 13:23","pubTimestamp":1721625780,"startTime":"0","endTime":"0","summary":"[下跌股]永泰生物-B(06978) 股价在下午01:23比前收市价下跌6.364%,现股价为港币$3.09。至目前为止,今日最高价为$3.09,而最低价为$3.09。总成交量为5000股,总成交金额为港币$1.545万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407221450/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2453771750","title":"【兴证医药】2024ESMO会议国产创新药品种梳理","url":"https://stock-news.laohu8.com/highlight/detail?id=2453771750","media":"兴证医药健康","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453771750?lang=zh_cn&edition=full","pubTime":"2024-07-22 11:59","pubTimestamp":1721620740,"startTime":"0","endTime":"0","summary":"在任何情况下,作者及作者所在团队、兴业证券股份有限公司不对任何人因使用本平台中的任何内容所引致的任何损失负任何责任。本平台旨在沟通研究信息,交流研究经验,不是兴业证券股份有限公司研究报告的发布平台,所发布观点不代表兴业证券股份有限公司观点。任何完整的研究观点应以兴业证券股份有限公司正式发布的报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA4NjAxNzEzNw==&mid=2650184947&idx=1&sn=2f7b145eeaa05d326d75f124d093d5ff&chksm=86db3a70d73efda8a2f94b4367ab86fac24822e29d4b37668863fceb25bb504cb43d56fdc958&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["09939","06978","BK1515","BK1161","BK1574"],"gpt_icon":0},{"id":"2453767833","title":"氨基一周|BD不应该“神秘化”; 第七个被治愈的艾滋病患者出现了","url":"https://stock-news.laohu8.com/highlight/detail?id=2453767833","media":"氨基观察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453767833?lang=zh_cn&edition=full","pubTime":"2024-07-22 11:13","pubTimestamp":1721618012,"startTime":"0","endTime":"0","summary":"\"氨基一周\"致力于提供\"全球最重要的大健康产业新闻分析\",深入挖掘行业动态,洞察市场趋势。无论您是行业从业者还是对大健康产业感兴趣的读者,\"氨基一周\"都将是您了解行业脉动的得力助手。欢迎关注我们,一起探索大健康产业的无限可能。本周,\"氨基一周\"带来的产业动态分析要点包括:BD不应该越来越“神秘”第七个被治愈的...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240722A037XG00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240722A037XG00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["PFS","LU1196500208.SGD","LU2602419157.SGD","LU0466842654.USD","LU0889566641.SGD","LU1162221912.USD","LU1066053197.SGD","BK4195","LU1430594728.SGD","BK4588","BMI","LU1032466523.USD","LU0114720955.EUR","LU0882574055.USD","BK1161","LU1221951046.USD","BK4157","LU1244550221.USD","IE00BSNM7G36.USD","LU1032955483.USD","BK1574","LU1506573853.SGD","06978","BK4568","LU0640476718.USD","LU1732799900.SGD","LU0795875169.SGD","BK4550","IE00B19Z3581.USD","LU0795875086.SGD","LU1059921491.USD","LU1074936037.SGD","BK4504","JNJ","LU0345770308.USD","LU1935042991.SGD","BK4585","SG9999002224.SGD","LU2133065610.SGD","BK4592","LU1929549753.HKD","BK4559","LU1066051225.USD","LU1066051498.USD","LU1244550494.USD","BK4581","LU1221951129.SGD","IE000M9KFDE8.USD","LU0345770993.USD","BK4007"],"gpt_icon":0},{"id":"2453789532","title":"港股异动 | 和黄医药(00013)再涨超5% 公司近期介绍创新药物进展 机构称研发进展迅速","url":"https://stock-news.laohu8.com/highlight/detail?id=2453789532","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453789532?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:42","pubTimestamp":1721616141,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,和黄医药(00013)再涨超5%,截至发稿,涨5.41%,报31.2港元,成交额4428.23万港元。消息面上,7月9日,和黄医药举办2024年研发日交流活动,公司管理层在会议中重点分享了候选创新管线的临床数据与市场价值,包括索乐匹尼布在自身免疫性疾病的临床数据及优势分析、索凡替尼在胰腺癌的治疗潜力、HMPL-306用于治疗急性髓系白血病的早期数据分析及III期临床设计。东北证券指出,公司近期研发进展迅速,多产品同步发力,展现了优异的临床数据和竞争格局,并不断推进产品全球化,预计将持续催化公司基本面价值提升。另外,公司管线储备丰富,产品市场空间广阔,不断实现海外放量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSCEI","BK1588","BK1191","BK4585","BK1587","HCM","HSTECH","YANG","BK1161","BK4588","00013","BK4007","BK4531","159992","06978","BK1574"],"gpt_icon":1},{"id":"2453783860","title":"细胞免疫治疗概念盘中拉升,*ST龙津涨4.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453783860","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453783860?lang=zh_cn&edition=full","pubTime":"2024-07-22 09:50","pubTimestamp":1721613003,"startTime":"0","endTime":"0","summary":"07月22日,细胞免疫治疗概念盘中拉升,截至09点49分,细胞免疫治疗概念整体指数上涨0.58%,报632.900点。从个股上来看,该概念的成分股中,*ST龙津涨4.37%,ST百灵、普蕊斯、药明康德涨幅居前。从资金上来看,截止发稿,细胞免疫治疗概念主力净流入为-309.85万,其中药明康德受到资金热捧,主力净流入3117.88万;拉长时间线来看,该板块近20日主力资金净流入-29.47亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722095003941f8fc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722095003941f8fc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2045819591.USD","06978","BK1583","LU0708995583.HKD","LU0052750758.USD","LU2242644610.SGD","BK1574","02359","LU1046422090.SGD","LU0320764599.SGD","BK1576","603259","BK1141","LU2125910500.SGD","BK1161"],"gpt_icon":0},{"id":"2452446444","title":"永泰生物-B盘中异动 临近收盘快速下挫7.41%报3.001港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452446444","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452446444?lang=zh_cn&edition=full","pubTime":"2024-07-19 15:55","pubTimestamp":1721375755,"startTime":"0","endTime":"0","summary":"2024年07月19日临近收盘15时55分,永泰生物-B股票出现波动,股价快速下跌7.41%。截至发稿,该股报3.001港元/股,成交量1.6万股,换手率0.00%,振幅1.23%。资金方面,该股资金流入0港元,流出4.844万港元。永泰生物-B股票所在的生物技术行业中,整体跌幅为0.69%。其相关个股中,创胜集团-B、宜明昂科-B、泰格医药涨幅较大,振幅较大的相关个股有华领医药-B、华康生物医学、锦欣生殖,振幅分别为20.00%、17.59%、14.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719155555941f8b23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719155555941f8b23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1161","BK1574"],"gpt_icon":1},{"id":"2452444693","title":"永泰生物-B(06978)股价下跌6.173%,现价港币$3.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2452444693","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452444693?lang=zh_cn&edition=full","pubTime":"2024-07-19 15:55","pubTimestamp":1721375700,"startTime":"0","endTime":"0","summary":"[下跌股]永泰生物-B(06978) 股价在下午03:55比前收市价下跌6.173%,现股价为港币$3.04。至目前为止,今日最高价为$3.04,而最低价为$3.04。总成交量为1.1万股,总成交金额为港币$3.344万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407194180/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2452499039","title":"中信建投:自免市场规模加速发展 推动国内创新药产业提质增效","url":"https://stock-news.laohu8.com/highlight/detail?id=2452499039","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452499039?lang=zh_cn&edition=full","pubTime":"2024-07-19 09:53","pubTimestamp":1721353996,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,中信建投证券发布研报称,自身免疫类疾病与II型炎症的患者规模正在迅速增长,市场规模虽然仅次于肿瘤药物,但仍然处于加速发展期。呼吸系统疾病中,哮喘人数最多,占据市场份额最大。皮肤系统疾病中,特应性皮炎与银屑病占据了最主要的市场地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","601066","06978","BK1574","BK1161","BK0276"],"gpt_icon":0},{"id":"2452437993","title":"中国生物制药(01177.HK)1类创新药库莫西利胶囊的新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452437993","media":"港股解码","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452437993?lang=zh_cn&edition=full","pubTime":"2024-07-18 17:31","pubTimestamp":1721295084,"startTime":"0","endTime":"0","summary":"【财华社讯】中国生物制药(01177.HK)公布,集团开发的1类创新药库莫西利胶囊“Culmerciclib(TQB3616)”联合氟维司群注射液用于既往内分泌经治的激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性局部晚期或转移性乳腺癌的III期临床试验(NCT05375461)已完成期中分析,经独立数据监查委员会(IDMC)审核,达到预设的主要终点,...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OnJC5UF9P_vW-bZGFGxgPFTrnmv2NCCrb5v4iKJVUcxBcAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OnJC5UF9P_vW-bZGFGxgPFTrnmv2NCCrb5v4iKJVUcxBcAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240718A07I4500","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240718A07I4500","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["01177","BK1515","BK1191","BK1589","06978","BK1574","BK1161","BK1521"],"gpt_icon":0},{"id":"2452172541","title":"中国生物制药(01177):1类创新药库莫西利胶囊“Culmerciclib(TQB3616)”新药上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452172541","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452172541?lang=zh_cn&edition=full","pubTime":"2024-07-18 16:36","pubTimestamp":1721291768,"startTime":"0","endTime":"0","summary":"智通财经APP讯,中国生物制药 发布公告,集团开发的1类创新药库莫西利胶囊“Culmerciclib”联合氟维司群注射液用于既往内分泌经治的激素受体阳性、人表皮生长因子受体2阴性局部晚期或转移性乳腺癌的III期临床试验已完成期中分析,经独立数据监查委员会审核,达到预设的主要终点,研究结果将在学术期刊或重大学术会议上予以公布。集团已向中国国家药品监督管理局药品审评中心递交新药上市申请并获受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1161","01177","159992","06978","BK1589","BK1515","BK1521","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":0.0383},{"period":"3month","weight":0.035},{"period":"6month","weight":-0.228},{"period":"1year","weight":-0.2262},{"period":"ytd","weight":-0.35}],"compareEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.0218},{"period":"3month","weight":0.048},{"period":"6month","weight":0.1092},{"period":"1year","weight":-0.0755},{"period":"ytd","weight":0.0345}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.129933},{"month":2,"riseRate":0.5,"avgChangeRate":0.104699},{"month":3,"riseRate":0.25,"avgChangeRate":-0.117615},{"month":4,"riseRate":0.25,"avgChangeRate":-0.077145},{"month":5,"riseRate":0.5,"avgChangeRate":0.017788},{"month":6,"riseRate":1,"avgChangeRate":0.116747},{"month":7,"riseRate":0,"avgChangeRate":-0.110144},{"month":8,"riseRate":0.5,"avgChangeRate":-0.036515},{"month":9,"riseRate":0.25,"avgChangeRate":-0.028227},{"month":10,"riseRate":0.75,"avgChangeRate":0.082892},{"month":11,"riseRate":0.5,"avgChangeRate":-0.017056},{"month":12,"riseRate":0.75,"avgChangeRate":0.09355}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}